不同放化疗治疗模式对肺癌患者放射性肺炎发生的影响
DOI: 10.3971/j.issn.1000-8578.2018.18.0065
Keywords: A Retrospective Study,Diffusion-weighted Magnetic Resonance Imaging Evaluates Salivary Gland Function Damage in Nasopharyngeal Carcinoma Patients Treated with Intensity-modulated Radiation Therapy,Advances of 125I Radioactive Particle Chain Intracavitary Brachytherapy,Effect of Selective Increase of Single Dose of PTV on Prognosis of Patients with Esophageal Cancer,Evaluation of 192Ir-Based Hypofractionated Stereotactic Ablative Brachytherapy as A Neoadjuvant Treatment for Operable Peripheral Non-small Cell Lung Cancer,Research Progress of Radiation-indnced Heart Disease,Whole Brain Radiotherapy Combined with Simultaneous Integrated Boost for Brain Metastases of Lung Cancer: Its Clinical Effectiveness and Prognosis,Prophylactic Radiotherapy for Procedure Tract Metastases in Malignant Pleural Mesothelioma: A Meta-analysis,Comparison of Efficiency and Safety Between Radiofrequency Ablation and Stereotactic Body Radiotherapy on Primary Small Hepatocellular Carcinoma,Carbon Ion Radiotherapies for Adenoid Cystic Carcinoma,Patterns of Failure After Radical Surgery on Patients with StageⅡ/Ⅲ Thoracic Esophageal Squamous Cell Carcinoma,Relationship Between NF-κB and Epithelial-to-mesenchymal Transition of Radiationinduced Human Esophageal Carcinoma Cells,Effect of Intensity Modulated Radiotherapy Combined with Hormonal Therapy on Fatigue in Patients with Locally Advanced Prostate Cancer,Prognosis of Clinical Stage ⅢA(N2) Non-small Cell Lung Cancer Patients Received Radiotherapy
Abstract:
摘要 目的 比较肺癌放疗患者不同放化疗治疗模式下2级以上放射性肺炎(RP)发生的差异,以及临床治疗特征对RP发生的影响。方法 回顾性分析自2014年1月至2016年1月在我院行放化疗综合治疗的肺癌患者136例,按期随访并复查肺功能、胸部CT,按RTOG急性放射肺炎评价标准对肺损伤分级进行评价,分析临床特征及治疗模式对RP发生的影响。结果 ≥2级RP 36例,发生率为26.5%。临床特征方面,粉尘接触史和病理类型与RP发生有一定相关性(P=0.048, 0.047),其余指标方面差异均无统计学意义。治疗模式方面,序贯放化疗与同步放化疗比较,在总RP发生、2级和3级RP发生率方面差异均无统计学意义,而≥4级RP发生率两组比较差异有统计学意义(6.7% vs. 0, P=0.05)。不同化疗方案之间比较在≥2级RP发生方面差异无统计学意义。RP严重程度与总化疗周期数及诱导化疗周期数呈显著正相关(P=0.000)。结论 粉尘接触史和病理类型是临床特征方面增加RP发生的独立因素。不同治疗模式对RP的发生有一定的影响,其中与患者化疗周期数密切相关,特别是总化疗周期或诱导化疗周期
Full-Text